Patient-to-Patient Supply for Cell Immunotherapies Summit

29/10/2020 - 30/10/2020
Online

Achieving Standardization & Operational Excellence in Vein-to-Vein Supply

As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.

From temperature and time sensitivity, to patient-facing delivery and chain of identity, these supply chain challenges must be overcome to ensure the delivery of safe and efficacious cell therapies at scale.

The Patient-to-Patient Supply for Cell Immunotherapies Summit (October 29-30, 2020) is a unique two-day digital platform discussing best practises in implementing robust vein-to-vein supply chains.

Our community of supply chain experts are looking forward to connecting with you in the digital world, including:

  • Christopher Baldwin, Supply Chain Director, Cell & Gene Therapy¸ GSK
  • Reggie Foster, Senior Director Labelling, Logistics & Packaging, Kite: a Gilead Company
  • Sheng Lin-Gibson, Chief, NIST Biosystems & Biomaterials Division
  • Jean Stanton, Director Commercial Apheresis, Johnson & Johnson
  • Richard McFarland, President, Standards Coordinating Body
  • Neeraj Shah, Director Supply Chain Excellence, Bristol-Myers Squibb
  • Kawa Chiu, VP CMC Supply Chain, Lyell Immunopharma
  • Alexandra Gomez, Associate Director, Patient Services Operations, bluebird bio

Get your copy of the brand-new agenda for the full list of speakers and sessions.

Join the key speakers sharing industry-leading expertise and reconnect with your community to ensure your team is equipped to navigate this pandemic with robust, commercially ready supply chains.

Join this timely discussion by registering online today.